Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 37 clinical trials
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE)

The overall aim of this trial, which is called STAMPEDE, is to assess novel approaches for the treatment of men with prostate cancer who are starting long-term ADT for the first time, termed hormone-naïve prostate cancer. This trial aims to see if we can improve the way in which prostate …

hormone therapy
testosterone
adenocarcinoma
antiandrogen therapy
androgens
  • 3825 views
  • 04 May, 2022
  • 115 locations
Additional Treatments to the Local Tumour for Metastatic Prostate Cancer: Assessment of Novel Treatment Algorithms (IP2-ATLANTA)

Local cytoreductive treatments for men with newly diagnosed metastatic prostate cancer in addition to standard of care treatment

metastatic prostate cancer
prostatectomy
metastasis
prostate cancer metastatic
  • 51 views
  • 13 Feb, 2022
  • 13 locations
Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence

This study evaluates the value of Gallium-68 labeled PSMA (68Ga-PSMA) for PET/CT imaging of prostate cancer recurrence. 68Ga-PSMA is a radioactive molecule, which binds to prostate cancer cells. Together with a PET/CT scanner, the distribution of 68Ga-PSMA can be determined in the body. To test this new drug, participants will …

definitive treatment
pet/ct scan
cancer
prostate specific antigen
adenocarcinoma
  • 0 views
  • 26 Feb, 2022
  • 1 location
PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases (STORM)

A proportion of prostate cancer (PCa) patients develop relapse following curative local treatment. Regional nodal recurrence is an emerging clinical situation since the introduction of new molecular imaging methods in the restaging of recurrent prostate cancer. More specifically, a subgroup of these patients is being diagnosed with a recurrence confined …

adenocarcinoma
antiandrogen therapy
metastasis
stereotactic body radiotherapy
adenocarcinoma of prostate
  • 216 views
  • 04 Mar, 2022
  • 29 locations
Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer (IP4-CHRONOS)

Men diagnosed with significant cancer confined to the prostate currently undergo radical therapy directed to the whole prostate (radiotherapy or prostatectomy). These provide good cancer control but can cause significant side effects. Focal Therapy involves targeting the cancer alone, whilst leaving healthy prostate gland alone. Case series have shown similar …

cancer
testosterone
finasteride
adenocarcinoma
antiandrogen therapy
  • 13 views
  • 27 Feb, 2022
  • 8 locations
PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer

changes (both responders and non-responders), durations of response, emergence of treatment resistance, and the host reaction to the therapies. Of particular relevance to metastatic prostate cancer

pet/ct scan
metastatic prostate cancer
bone scan
aggressiveness
metastasis
  • 0 views
  • 16 Aug, 2021
  • 1 location
Hyperpolarized Carbon-13 Imaging of Metastatic Prostate Cancer

A pilot study with a group of up to 10 men with CRPC about to embark on a 6-month course of treatment with radium 223. Study participants will undergo anatomical MR imaging combined with the new hyperpolarized MRI (1 hour exam) prior to treatment.

castration-resistant prostate cancer
metastatic prostate cancer
prostate cancer metastatic
platelet count
neutrophil count
  • 652 views
  • 13 May, 2022
  • 1 location
The Effect of ADT on PSMA Expression in Metastatic Prostate Cancer (ADTPSMA2)

Thirty-five men with newly diagnosed, metastatic prostate cancer are scanned with 18F-PSMA 1007 PET/CT at baseline, 3 weeks after the initiation of GnRH-antagonist, at one year and at the time

castration-resistant prostate cancer
pet/ct scan
carcinoma
metastatic prostate cancer
adenocarcinoma
  • 0 views
  • 21 Feb, 2022
  • 1 location
Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET Scanning (PICT-01)

Various approaches are currently being developed for prostate cancer immunotherapy. However, a major challenge facing the development of cancer immunotherapy is the identification of tumors that would best respond to this type of treatment. Different studies suggest that prostate cancer more likely to progress are more infiltrated by exhausted T …

immunological adjuvant
androgen suppression
metastatic prostate cancer
antiandrogen therapy
prostatectomy
  • 1 views
  • 24 Feb, 2022
  • 1 location
The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer

To goal of this research is to assess the ability of Gallium-68 (68Ga) Prostate-Specific Membrane Antigen-11 (PSMA-11) positron emission tomography/computed tomography (PET/CT) to increase diagnostic accuracy in localizing primary and metastatic lesions in patients with suspected prostate cancer and elevated Prostate Imaging Reporting and Data System (PI-RADS) scores and Prostate-Specific …

pet/ct scan
digital rectal examination
prostate specific antigen
metastatic prostate cancer
positron emission tomography
  • 35 views
  • 22 Mar, 2022
  • 1 location